Vaccine Challenge Studies Could Shrink Phase III Trials - Aventis' Lindberg
Executive Summary
The use of vaccine challenge studies could reduce the size of Phase III trials, Aventis Pasteur Exec VP-Research & Development Alf Lindberg said at the World Vaccine Congress in Paris Sept. 19.